Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety confirmation study of 5 or more cycles of Akalux photoimmunotherapy in unresectable or recurrent head and neck cancer
jRCT2041230050Active, not recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Jun 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab sarotalocan sodium in head and neck cancer (HNC), sponsored by Rakuten Medical, Inc. Primary endpoint: Primary safety endpoint. Started Jun 2023; status: active, not recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT2041230050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230050.